Syndax Pharmaceuticals, Inc. (SNDX)
19.57
-0.08
(-0.41%)
USD |
NASDAQ |
Aug 24, 16:00
19.70
+0.13
(+0.66%)
After-Hours: 20:00
Syndax Pharmaceuticals Enterprise Value : 1.786B for Aug. 24, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 24, 2026 | 1.786B |
| August 21, 2026 | 1.793B |
| August 20, 2026 | 1.802B |
| August 19, 2026 | 1.893B |
| August 18, 2026 | 1.817B |
| August 17, 2026 | 1.803B |
| August 14, 2026 | 1.810B |
| August 13, 2026 | 1.743B |
| August 12, 2026 | 1.807B |
| August 11, 2026 | 1.850B |
| August 10, 2026 | 1.858B |
| August 07, 2026 | 1.860B |
| August 06, 2026 | 1.803B |
| August 05, 2026 | 1.817B |
| August 04, 2026 | 1.743B |
| August 03, 2026 | 1.757B |
| July 31, 2026 | 1.740B |
| July 30, 2026 | 1.778B |
| July 29, 2026 | 1.755B |
| July 28, 2026 | 1.792B |
| July 27, 2026 | 1.871B |
| July 24, 2026 | 1.897B |
| July 23, 2026 | 1.932B |
| July 22, 2026 | 2.007B |
| July 21, 2026 | 2.060B |
| Date | Value |
|---|---|
| July 20, 2026 | 2.029B |
| July 17, 2026 | 2.074B |
| July 16, 2026 | 2.066B |
| July 15, 2026 | 2.138B |
| July 14, 2026 | 2.193B |
| July 13, 2026 | 2.082B |
| July 10, 2026 | 2.146B |
| July 09, 2026 | 2.256B |
| July 08, 2026 | 2.231B |
| July 07, 2026 | 2.113B |
| July 06, 2026 | 2.010B |
| July 02, 2026 | 1.987B |
| July 01, 2026 | 1.904B |
| June 30, 2026 | 1.990B |
| June 29, 2026 | 1.922B |
| June 26, 2026 | 1.880B |
| June 25, 2026 | 1.747B |
| June 24, 2026 | 1.762B |
| June 23, 2026 | 1.730B |
| June 22, 2026 | 1.704B |
| June 18, 2026 | 1.676B |
| June 17, 2026 | 1.679B |
| June 16, 2026 | 1.636B |
| June 15, 2026 | 1.630B |
| June 12, 2026 | 1.609B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Viking Therapeutics, Inc. | 3.379B |
| Kura Oncology, Inc. | 608.46M |
| ACADIA Pharmaceuticals, Inc. | 4.221B |
| Alnylam Pharmaceuticals, Inc. | 31.24B |
| Anika Therapeutics, Inc. | 272.43M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -49.36M |
| Revenue (Quarterly) | 72.79M |
| Total Expenses (Quarterly) | 122.15M |
| EPS Diluted (Quarterly) | -0.5547 |
| Gross Profit Margin (Quarterly) | 95.59% |
| Profit Margin (Quarterly) | -67.82% |
| Earnings Yield | -12.87% |
| Normalized Earnings Yield | -12.87 |